Team receives Association of Community Cancer Centers Innovator Award

A team of Vanderbilt employees have received and award for implementing a streamlined follow-up protocol for patients who may not know they have cancer.

The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.

Prediction models for breast cancer

Vanderbilt researchers developed new prognostic models for breast cancer outcomes and found that adding postdiagnostic weight change as a factor improves the prediction.

Madison Adolph, PhD, left, David Cortez, PhD, and Archana Krishnamoorthy are studying fundamental processes involved in DNA replication.

Researchers discover that protein switches functions to regulate DNA replication

Vanderbilt biochemists have discovered what the DNA damage response protein RADX does — and how it does it.

National Black Family Cancer Awareness Week is call to action

National Black Family Cancer Awareness Week, June 17-23, aims to spur conversations followed by actions to make advancements in care more equitable.

1 2 3 4 5 6 23